Lisa Frölich

CAR-HEMATOTOX: a model for CAR T-cell–related hematologic toxicity in relapsed/refractory large B-cell lymphoma

Kai Rejeski, Ariel Perez Perez, Pierre Sesques et al. · Blood · 2021 · 441 citations · Full text

Life Sciences, Hematology, Immunology +16

Identifying Early Infections in the Setting of CRS With Routine and Exploratory Serum Proteomics and the HT10 Score Following CD19 CAR-T for Relapsed/Refractory B-NHL

Kai Rejeski, Viktoria Blumenberg, Gloria Iacoboni et al. · HemaSphere · 2023 · 38 citations · Full text

Life Sciences, Immunology, Oncology +17

Oligoclonal T-cell expansion in a patient with bone marrow failure after CD19 CAR-T therapy for Richter-transformed DLBCL

Kai Rejeski, Zhijie Wu, Viktoria Blumenberg et al. · Blood · 2022 · 35 citations · Full text

Medicine, Hematology, Oncology +17

Inferior Outcomes of EU Versus US Patients Treated With CD19 CAR-T for Relapsed/Refractory Large B-cell Lymphoma: Association With Differences in Tumor Burden, Systemic Inflammation, Bridging Therapy Utilization, and CAR-T Product Use

Veit Bücklein, Ariel Perez Perez, Kai Rejeski et al. · HemaSphere · 2023 · 35 citations · Full text

Medicine, Hematology, Oncology +17

Early quantification of anti-CD19 CAR T cells by flow cytometry predicts response in R/R DLBCL

Viktoria Blumenberg, Galina Busch, S. Baumann et al. · Blood Advances · 2023 · 33 citations · Full text

Life Sciences, Hematology, Oncology +14